Connect with us

Featured Stocks

Helix TCS Inc (OTCMKTS: HLIX) Becoming a Cannabis Powerhouse Slowly But Steadily



Helix TCS

The marijuana industry is, without a doubt, a rapidly growing market. However, several regulations keep on changing, and operators highly rely on the most trusted technology solutions to focus their business as well as navigate complexities.

Therefore, only the best stock is what they look after. Likely enough, Helix TCS Inc (OTCMKTS: HLIX) provides the marijuana industry’s most powerful as well as effective critical infrastructure services. Notably, the firm has the market’s leading brands such as BioTrackTHC, Amercanex, Helix Security, and CannaBase with it, which help the company to meet and exceed their requirements.

HLIX 101

Helix TCS Inc. is the leading provider of ancillary services for the marijuana industry in the US. The stock helps owners as well as operators of the licensed marijuana business to stay competitive and compliant as they mitigate risks.

The stock’s products are available to over 2,000 customer locations in almost 33 states and 5 countries. Besides, they have (thus far) processed more than $18 billion in marijuana sales. The numbers may seem impressive, but what lies ahead is somewhat more promising.

HLIX Price Analysis

One area that HLIX stock has not impressed lately is its price, which has been on the downtrend over the past year now. However, it has to be believed that similar market segments have not been very popular in that period, and hence, the declining price tendency may be having last breaths.

Currently, the price of Helix stock stands at $1.68, and it may not be long before we start seeing another upward trajectory. Nevertheless, the stock is off its 52-week high of about $4.01 that it experienced a year ago.

The latest developments, as well as acquisitions the stock has made, may soon prove to be the catalysts for Helix to hit new highs.

HLIX price today.

Helix TCS, Inc. Doing Everything Right for a Breakthrough

In ensuring that the stock remains on track for a breakout, it has thus far made several acquisitions as well as developments. The results of the events may have been highlighted from the report on Helix’s Q1 of 2019.

Preparations for Cannabis as a Commodity

The company has already prepared for cannabis as a commodity by acquiring Amercanex International Exchange. The acquisition is a step further for the stock positioning itself as the leader in the development of modern marijuana market.

Acquired merely two months ago, Amercanex International Exchange is the most influential marijuana electronic trading platforms. Its acquisition provides Helix TCS with a Sophisticated Electronic Communications Network (ECN) which can integrate blockchain technology in facilitating real-time transactions in the market.

It also enables transaction capabilities in several cannabis markets in the US and internationally.

The Contract Extension with Hawaii

Not too long ago, the stock extended its cannabis tracking contract with Hawaii. In the one-year contract, its subsidiary Bio Track THC will be providing the state with medical cannabis traceability system.

Further international Footprint for Helix TCS into Europe: The stock also expanded its reach with licensed cannabis cultivators as well as manufactures in the UK using BioTrackTHC. By doing so they’ll be able to meet the ever-expanding demand in the industry.

The Leading Point of Sale

The company was ranked top revenue-generating ancillary business two months ago by the Cannabis Business Executive. It’s a significant achievement which not only shows that the stock is doing great but also indicates that Helix is on the right track now.

Subsequently, all the developments had shown positive results in the recent Q1 2019 report. If we talk about the numbers, the revenues increased 199% to $3.37 million with a gross profit of $1.45 million, a gross margin of 43%.

What Now for Helix TCS?

As cannabis moves closer to federal legalization in the United States, Helix TCS is one of the best stocks well positioned to proliferate in line with the entire market. With a steady and smart leadership, Helix is poised for way more growth than many think it can.

For the latest updates on HLIX and the hottest MJ stocks, sign up below!

Disclosure: We have no position in HLIX and have not been compensated for this article.

Image courtesy of Pexels

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play



Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…

Continue Reading

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment



Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of…

Continue Reading

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020



OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.


Continue Reading

MJ Stocks